On July 13, 2023, the FDA approved the first over-the-counter birth control called ‘Opill’. An increased availability of hormonal birth control without a prescription may increase access and remove the barriers that individuals
On July 18th, 2023, the FDA approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) in neonates and infants born during or entering their first RSV season, and in children up
